#6: Addressing Life Expectancy through Nudges, Financial incentives & Disincentives (ft. Maria Kasimati)

07/23/23 • 58 min

This episode is a must listen.
In this episode of Global Health Conversations, I spoke to Maria Myrto Kasimati, MHCM, a scientific expert specialized in immunology and public health currently working for Havas Just:: as a Medical Writer.
We talked about nudges, financial incentives, financial discincentives and using these health economics and policy approaches in addressing the causes affecting reduced life expectancy. It was an interesting talk - an unofficial Part 2 to Episode 3 structured as a discussion.
Connect with Mary here: https://www.linkedin.com/in/maria-myrto-kasimati-mhcm-92139314b/
Resources:

1. Nudges Versus Financial Incentives (abstract) (2023)
2. Changes in life expectancy and house prices in London from 2002 to 2019: hyper-resolution spatiotemporal analysis of death registration and real estate data (Full paper)
3. World Bank - Life Expectancy at Birth (years) (up to 2021)
4. Key Data on Health and Health Care by Race and Ethnicity (2023)
5. CDC Vital Statistics Surveillance Report (2021)
Sign up to the Fortnightly Newsletter:
https://globalhealthconversations.substack.com/?utm_source=substack&utm_medium=web&utm_campaign=substack_profile
I would love your feedback. Feel free to e-mail me here: [email protected]

Support the show

Support the show

Previous Episode

#5: CRISPR, Gene Editing, Access to Biotherapeutics & On-target approaches to the PhD journey (ft. Margareta Rybarikova)

Subscribe to the Global Health Conversations Newsletter to be updated on the latest interviews and episodes 🤩 : https://globalhealthconversations.substack.com/?utm_source=substack&utm_medium=web&utm_campaign=substack_profile
Margareta Rybarikova is a current PhD candidate with a keen interest in the development of novel therapies for genetic disorders. She received her Bachelor's degree in Biomedical Sciences from Brunel University London, where she focused on gene therapy, genomic medicine, molecular pharmacology, and cellular pathologies.

Margareta went on to complete a Master's degree in Genes, Drugs, and Stem Cells - Novel Therapies at Imperial College London, where she was elected as the Course Representative. For her MSc project, she explored AAV-mediated gene editing with small Cas9 nucleases for Huntington's disease. Her passion for genetic therapy led her to pursue a PhD at the CHUV, as part of the Lemanic Neuroscience Doctoral School in Lausanne. In her doctoral research, she is developing a CRISPR-Cas9 system for ATXN3 gene editing in Spinocerebellar ataxia type 3 (SCA3).

A friend of the podcast, Margareta discusses her research, gene therapies as a frontier in tackling rare diseases, access to biotherapeutics and balancing life and science and scientific career paths.

Support the show

Next Episode

BONUS: The Case of a Clinical Trial Catastrophe - The TGN1412 ‘Elephant Men’ Clinical Trial

This episode is a little different. Today's episode is a story looking at the case of the TGN1412 CIinical Trial. A trial that went terribly wrong.
I thoroughly enjoyed making this episode and have a number of ideas for similar ones. If you liked this bonus episode, please leave a 5 star rating so that I know you're interested to hear more in future.
In March of 2006, a clinical trial for the drug TGN1412 gathered eight young and healthy men as volunteers. Within a mere 16 hours, all six were urgently transferred to Northwick Park Hospital's intensive care unit due to severe and life-threatening reactions.

This catastrophic event, now infamously known as the 'Elephant Man Drug Trial,' sent shockwaves rippling through the medical and pharmaceutical communities. TGN1412, a groundbreaking monoclonal antibody drug developed by TeGenero, a German biotech company, had held the promise of treating autoimmune diseases and leukemia. Paraxel, a prominent contract research organization, was responsible for conducting the Phase I trial, the critical first-in-human testing, within an independent clinical trials unit at Northwick Park.

Prior to the trial, comprehensive clinical and animal testing, including studies involving non-human primates, had been diligently carried out. These preliminary tests had seemingly indicated no signs of safety issues.
Subscribe to the newsletter to be notified of future bonus episodes and news from the world of global health: https://globalhealthconversations.substack.com/?utm_source=substack&utm_medium=web&utm_campaign=substack_profile
Contact me: [email protected]
Expert group on Clinical Trials report: Duff GW, et al. (Expert Group on Phase One Clinical Trials) (7 December 2006). Expert Group on Phase One Clinical Trials: Final report (Report).
Excellent, open-access paper looking at the biochemical phenomenon behind this case. Revisiting CD28 Superagonist TGN1412 as Potential Therapeutic for Pediatric B Cell Leukemia: A Review*Correction: The compensation that the 6 affected participants received was £2mil to be split between the 6 participants.

Support the show